畅享海角平台破解平台-海角社区官网官方入口

您好,歡迎光臨欣博盛生物科技商城!
服務(wù)熱線:400 680 0892
新聞資訊 News

BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

2023-09-01
瀏覽次數(shù): 252

BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

?

產(chǎn)品描述:

9D9-CP008單克隆抗體是原始9D9單克隆抗體的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始9D9克隆號相同,但是恒定區(qū)序列已經(jīng)從小鼠IgG2b變?yōu)樾∈驣gG2a。9D9-CP008單克隆抗體在Fc片段中也含有LALA-PG突變,使其無法與內(nèi)源性Fcγ受體結(jié)合。

?

9D9-CP008單克隆抗體能與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應(yīng),CTLA-4也稱為CD152。CTLA-4是一種33 kDa的細胞表面受體,由屬于免疫球蛋白超家族CD28家族的Ctla4基因編碼。CTLA-4在活化的T淋巴細胞和B淋巴細胞上表達。CTLA-4在結(jié)構(gòu)上類似于T細胞共刺激蛋白CD28,兩種分子都與B7家族成員B7-1 (CD80)和B7-2 (CD86)結(jié)合。在與配體結(jié)合時,CTLA-4負調(diào)節(jié)細胞介導的免疫反應(yīng)。CTLA-4在誘導和/或維持免疫耐受、胸腺細胞發(fā)育和保護性免疫調(diào)節(jié)中起作用。CTLA-4在免疫下調(diào)中的關(guān)鍵作用已經(jīng)在CTLA-4缺陷小鼠中得到證實,這些小鼠在3-5周齡時由于淋巴增生性疾病的發(fā)展而死亡。CTLA-4目前是腫瘤免疫治療中的熱門免疫檢查點靶點之一。

?

產(chǎn)品詳情:

產(chǎn)品名稱

RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

產(chǎn)品貨號

CP008

產(chǎn)品規(guī)格

1mg

反應(yīng)種屬

Mouse

克隆號

9D9-CP008

同種型

Mouse IgG2b(switched from mouse IgG2a)

免疫原

Not available or unknown

實驗應(yīng)用

in vivo CTLA-4 neutralization*

Western blot*

*Reported for the original mouse IgG2b 9D9 antibody

產(chǎn)品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

純度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

無菌處理

0.2 μm filtration

純化方式

Protein A

分子量

150 kDa

小鼠病原檢測

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存條件

抗體原液保存在4°C,不能冷凍保存。

推薦抗體稀釋液

InVivoPure pH 7.0 Dilution Buffer(貨號IP0070)

?

該產(chǎn)品自上市已被多篇SCI文獻引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻引用:

應(yīng)用

文章

體內(nèi)CTLA-4中和

(in vivo CTLA-4?

neutralization)

1.?Dai, M., et al. (2015). 'Curing mice with large tumors by locally?

delivering combinations of immunomodulatory antibodies'?

Clin Cancer Res 21(5): 1127-1138.

2.?Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates?

acquired resistance to agonistic anti-CD40 treatment' Cancer Immunol?

Res 3(3): 236-244.

3.?Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory?

(OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T?

cells capable of driving robust antitumor immunity' Cancer Immunol?

Res 2(2): 142-153.

4.?Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived?

suppressor cell fate through TRAIL-R-mediated apoptosis' J Clin Invest?

124(6): 2626-2639.

5.?Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in?

antibody-drug conjugates induce antitumor immunity by stimulation of?

dendritic cells' Cancer Immunol Res 2(8): 741-755.

6.?Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute?

to the antitumor activities of immunoregulatory receptor-targeting?

antibodies' J Exp Med 210(9): 1685-1693.

?

?

?

BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

更多產(chǎn)品詳情請咨詢 BioXCell 中國授權(quán)代理——欣博盛生物

全國服務(wù)熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?

深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????

廣州:020-87615159????????? ?上海: 021-34613729

代理品牌網(wǎng)站: www.yuebanme.com?

自主品牌網(wǎng)站: www.neobioscience.net

分享到:
關(guān)注欣博盛公眾號
Copyright ?2021 - 2023 深圳欣博盛生物科技有限公司
  網(wǎng)站地圖
犀牛云提供企業(yè)云服務(wù)